Guggenheim analyst Yatin Suneja notes Johnson & Johnson (JNJ) released two abstract titles for the upcoming European Congress of Rheumatology conference that indicate the company will be presenting proof-of-biology Phase 2 trial results across rheumatoid arthritis, ulcerative colitis and Sjogren’s syndrome patients. Based on the titles, coupled with the fact that J&J held back the data prior to a rheumatology “flagship event,” the firm thinks J&J is likely to present good data that could read through positively to the class and AnaptysBio’s (ANAB) rosnilimab programs. The firm keeps a Buy rating on AnaptysBio shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio board authorizes $75M stock repurchase plan
- AnaptysBio sees cash runway through year-end 2027
- Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks
- AnaptysBio price target raised to $42 from $36 at JPMorgan
- Cautious Hold Rating on AnaptysBio Amid Mixed Clinical Trial Results and Strategic Uncertainties